why choose us

First received: June 19, 2023

Clinical Trial: A Phase ? Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: COVID-19

Study Type: INTERVENTIONAL


Official Title: A Multicenter, Randomized, Double-Blind, Controlled, Phase ? Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination to Evaluate Efficacy, S

Brief Summary: A Phase ? Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta)Protein Vaccine (Sf9 Cell) in Booster Vaccination to Evaluate Efficacy, Safety and Immunogenicity

Read more